Archives
- 2025-11
- 2025-10
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Experimental Procedures Information on the materials used
2022-05-05

Experimental Procedures Information on the materials used in this study and the details of how the in vivo and in vitro assays were performed are provided in Supplemental Information. Acknowledgments This research was supported by the National Research Foundation of Korea (NRF) grant funded b
-
Since we were able to reach
2022-05-05

Since we were able to reach low micromolar to sub-micromolar potency in both compound series (6 and 7), we were also keen on assessing the preliminary ADME profile (particularly with respect to plasma and liver microsomal stability) of the most active compounds from these series. As it is evident fr
-
The PK and the tissue distribution
2022-05-05

The PK and the tissue distribution profiles of 15k, 15j, 14d and 2 (Table 8) in male ICR mice were assessed. 15k, 15j, 14d all exhibited prolonged half-lives and improved plasma exposure. 15k achieved the highest concentration (15.45 μg/mL) in plasma among four compounds. The observation that 15j (S
-
When studying the potential of HATi for the
2022-05-05

When studying the potential of HATi for the treatment of inflammatory lung diseases, investigating lung tissue specific effects may be particularly relevant since local administration of small molecule inhibitors in lung tissue is possible and is already applied for inhaled glucocorticoids in the tr
-
H R antagonism can prevent
2022-05-05

H3R antagonism can prevent seizure development and improve working memory through the activation of histaminergic neurons (Huang et al., 2004, Zhang et al., 2003). In addition, we have recently found that H3R antagonism protects against ischemia-reperfusion injury via histamine-independent mechanism
-
br Methods br Involvement of HO
2022-05-04

Methods Involvement of HO-1 in rheumatic diseases Therapeutic strategy targeted HO-1 Based on the researches focusing on the effect of HO-1 in rheumatic diseases, amount of approaches targeting regulation of HO-1 have been arising (See Table 1 for summary). It has been shown that different
-
Treatment and control for IBD are targeted to
2022-05-04

Treatment and control for IBD are targeted to identify and eliminate the cause if possible, decrease intestinal inflammation, reduce diarrhea and vomiting, improve appetite, and promote weight gain. Methods include dietary manipulation with or without concurrent medical therapy such as corticosteroi
-
Several compounds have been described
2022-05-04

Several compounds have been described in the literature as inhibitors of the sGC. Among them, methylene blue and LY83583 () are not direct sGC inhibitors, but rather block cGMP formation by generating superoxide anion radicals that deactivate NO. Despite their extensive use in plethora of research s
-
The isoenzyme hGSTP is an
2022-05-04

The isoenzyme hGSTP1-1 is an attractive drug target due to its high levels of disease association (target validation) and druggability (target tractability) properties [5,6,[17], [18], [19], [20], [21]]. hGSTP1-1 functions as a homodimer protein [18]. Each monomer has two domains, an α/β domain (N-t
-
Glutathione in reduced form GSH
2022-05-04

Glutathione in reduced form (GSH, the tripeptide, γ-glutamyl cysteinyl glycine) is a non-enzymatic low-molecular-weight antioxidant necessary for the maintenance of a cellular redox state (Noctor et al., 2012). At the stage of the transition from germination to seedling growth the process of cell di
-
Pharmacologic approaches of inhibiting GSNOR activity have r
2022-05-04

Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications
-
Of what interest is the link between GSNOR and
2022-05-04

Of what interest is the link between GSNOR and NO in the plant response to Fe deficiency? On the one hand, NO acts as an important signal to help plants accommodate Fe deficiencies; on the other hand, surplus NO is indeed a harmful RNS that induces severe S-nitrosylation-related damage at a higher s
-
GW was also the starting point for a
2022-05-04

GW4064 was also the starting point for a study by an independent research group. The co-crystal structure of GW4064 with FXR suggested the potential for favorable hydrogen bond interactions between the isoxazole 3-aryl group and several receptor residues such as Tyr373 and Ser336. Replacing the 2,6-
-
QX 314 chloride synthesis One clue to how evolution
2022-05-04

One clue to how evolution has solved such spatiotemporal challenges comes from studies revealing that lymph node (LN) organization is more complex than originally presumed, suggesting that steady-state microanatomical features are crucial for effective immune responses (reviewed by Qi et al., 2014).
-
Petrat et al could show
2022-05-04

Petrat et al. could show, that even a low dosage of 10-mg/kg glycine (133 μmol/kg) has a beneficial effect on the small intestine after I/R. In regard to glycine, β-alanine has a clearly higher EC50 to the GlyR and activates the receptor with an efficiency of only 34.6%.16, 17 Therefore, it can be c
11176 records 141/746 page Previous Next First page 上5页 141142143144145 下5页 Last page